Published in Cancer Prev Res (Phila) on December 01, 2010
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) (2011) 1.61
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression. Oncotarget (2015) 1.04
miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget (2015) 0.97
Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer (2013) 0.90
Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. Oncologist (2013) 0.89
Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells. Virol J (2013) 0.86
Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced cyclin E. PLoS One (2013) 0.84
Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter. J Mol Med (Berl) (2014) 0.84
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Mol Cancer Ther (2013) 0.80
Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. Int J Oncol (2012) 0.80
ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression. Oncotarget (2016) 0.79
Oncolytic adenovirus targeting cyclin E overexpression repressed tumor growth in syngeneic immunocompetent mice. BMC Cancer (2015) 0.77
Effective Capture of Circulating Tumor Cells from a Transgenic Mouse Lung Cancer Model Using Dendrimer Surfaces Immobilized with Anti-EGFR. Anal Chem (2015) 0.77
Animal models in carotenoids research and lung cancer prevention. Transl Oncol (2011) 0.76
Expression Profiling and Proteomic Analysis of JIN Chinese Herbal Formula in Lung Carcinoma H460 Xenografts. Evid Based Complement Alternat Med (2013) 0.76
Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique. Oncol Lett (2015) 0.75
Cancer cell cycles. Science (1996) 21.29
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Maximizing mouse cancer models. Nat Rev Cancer (2007) 5.38
Deregulated cyclin E induces chromosome instability. Nature (1999) 4.75
Mechanism limiting centrosome duplication to once per cell cycle. Nature (2006) 4.69
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc (2009) 4.50
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev (2006) 4.06
KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc (2009) 3.61
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest (2009) 3.14
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Mouse models for human lung cancer. Genes Dev (2005) 2.59
Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol (2004) 2.48
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19
CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci (2007) 1.95
Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res (2005) 1.86
Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene (2006) 1.79
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol (2009) 1.76
Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A (2007) 1.61
Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene (2006) 1.39
Activation of the hedgehog pathway in a subset of lung cancers. Cancer Lett (2006) 1.34
Creation and use of a cre recombinase transgenic database. Methods Mol Biol (2009) 1.33
Overexpression of hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas. Lung Cancer (2009) 1.29
Therapeutic inhibition of Hedgehog-GLI signaling in cancer: epithelial, stromal, or stem cell targets? Cancer Cell (2008) 1.19
Genetically engineered mouse models in cancer research. Adv Cancer Res (2010) 1.18
Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res (1999) 1.18
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res (2009) 1.10
Centrosome abnormalities are frequently observed in non-small-cell lung cancer and are associated with aneuploidy and cyclin E overexpression. J Pathol (2006) 1.06
Chromosome abnormalities in human non-small cell lung cancer. Cancer Res (1992) 1.04
Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res (2000) 1.01
Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer (1985) 1.00
Progress and applications of mouse models for human lung cancer. Eur Respir J (2010) 0.84
Specific chromosomal aberrations in mouse lung adenocarcinoma cell lines detected by spectral karyotyping: a comparison with human lung adenocarcinoma. Cancer Res (2002) 0.84
Genomic instability: on the birth and death of cancer. Clin Transl Oncol (2007) 0.78
Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol (2004) 15.15
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19
Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene (2003) 2.02
The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res (2007) 1.81
Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res (2004) 1.68
A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst (2005) 1.67
Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A (2007) 1.61
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) (2011) 1.61
Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res (2002) 1.61
A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity. J Exp Med (2011) 1.41
Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol (2005) 1.30
G0S2 is an all-trans-retinoic acid target gene. Int J Oncol (2008) 1.23
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res (2004) 1.16
UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2002) 1.16
Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J Biol Chem (2004) 1.14
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res (2009) 1.10
A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. Cancer Res (2012) 1.09
UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther (2008) 1.09
Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem (2007) 1.07
Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity. Cancer Res (2011) 1.05
A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res (2007) 1.04
Microarray analysis uncovers retinoid targets in human bronchial epithelial cells. Oncogene (2003) 1.04
High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res (2009) 0.99
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther (2008) 0.98
Anaphase catastrophe is a target for cancer therapy. Clin Cancer Res (2011) 0.97
Involvement of microRNAs in lung cancer biology and therapy. Transl Res (2011) 0.96
Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. Cancer Res (2010) 0.96
Cyclin D1 as a target for chemoprevention. Lung Cancer (2003) 0.95
Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res (2004) 0.95
UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation. Mol Cancer Ther (2008) 0.94
Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting. BMC Cancer (2009) 0.92
Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2. Gene (2002) 0.92
Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta (2005) 0.91
Lung cancer prevention: the guidelines. Chest (2003) 0.91
Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Mol Cancer Ther (2012) 0.91
Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer (2013) 0.90
Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia. J Natl Cancer Inst (2007) 0.89
Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res (2005) 0.89
Tumor-suppressive microRNAs in Lung cancer: diagnostic and therapeutic opportunities. ScientificWorldJournal (2009) 0.87
Retinoid targets in cancer therapy and chemoprevention. Cancer Biol Ther (2003) 0.86
Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood (2013) 0.85
The retinoic acid paradox in cancer chemoprevention. J Natl Cancer Inst (2006) 0.83
Uncovering novel targets for cancer chemoprevention. Recent Results Cancer Res (2007) 0.82
Repression of cyclin D1 as a target for germ cell tumors. Int J Oncol (2007) 0.82
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Mol Cancer Ther (2013) 0.80
Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. Int J Oncol (2012) 0.80
Retinoid chemoprevention trials: cyclin D1 in the crosshairs. Cancer Prev Res (Phila) (2009) 0.79
A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. Chemotherapy (2012) 0.78
Gene profiling uncovers retinoid target genes. Methods Mol Biol (2007) 0.78
Fenretinide activates a distinct apoptotic pathway. J Natl Cancer Inst (2004) 0.78
Nonclassical retinoids and lung carcinogenesis. Clin Lung Cancer (2005) 0.78
Repression of exogenous gene expression by the retinoic acid target gene G0S2. Int J Oncol (2013) 0.77
Clinical link between p53 and angiogenesis in lung cancer. J Clin Oncol (2002) 0.77
Combining cytotoxic chemotherapy with cyclooxygenase-2 inhibition. J Clin Oncol (2003) 0.75
Tissue microarrays for hypothesis generation. J Natl Cancer Inst (2004) 0.75